Cartesian Therapeutics
RNAC
80 hedge funds and large institutions have $38M invested in Cartesian Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 14 closing their positions.
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
0.01% more ownership
Funds ownership: 1.17% → 1.18% (+0.01%)
8% less funds holding
Funds holding: 87 → 80 (-7)
34% less capital invested
Capital invested by funds: $57.2M → $38M (-$19.2M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.13M |
| 2 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$597K |
| 3 |
Morgan Stanley
New York
|
+$395K |
| 4 |
Millennium Management
New York
|
+$215K |
| 5 |
State Street
Boston,
Massachusetts
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
-$3.41M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$560K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$481K |
| 4 |
Bank of New York Mellon
New York
|
-$255K |
| 5 |
BlackRock
New York
|
-$226K |
RNAC Hedge Fund Activity: Q4 2023 in Review
80 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2023, worth a combined $38M — down 34% from $57.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RNAC and 8 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 25 added.
The largest buyer was Fidelity Investments, adding an estimated $5.13M. The largest seller was Madison Avenue Partners, cutting an estimated $3.41M.
- 80 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2023, down from 87 in Q3 2023.
- Funds reported $38M of Cartesian Therapeutics stock for Q4 2023, down 34% quarter-over-quarter.
- 8 funds opened new Cartesian Therapeutics positions in Q4 2023 and 14 closed out, a net change of -6 holders.
- The largest Cartesian Therapeutics buyer in Q4 2023 was Fidelity Investments, an estimated $5.13M added.
- The largest Cartesian Therapeutics seller in Q4 2023 was Madison Avenue Partners, an estimated $3.41M sold.
Based on aggregated 13F filings for Q4 2023.